Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

SCYX Relative to the S&P 500

SCYX Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the SCYNEXIS, Inc. (NASD:SCYX) seasonal charts above shows that a Buy Date of December 17 and a Sell Date of April 3 has resulted in a geometric average return of 3.49% above the benchmark rate of the S&P 500 Total Return Index over the past 10 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 10 years by an average of 46.52% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

To download SCYX seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: SCYX